-
Tytuł:
-
[Peptidergic nootropic therapy in cerebral palsy associated with epilepsy].
-
Autorzy:
-
Kholin AA; Neurology, Neurosurgery and Medical Genetics Department of Pediatric Faculty, Pirogov Russian National Research Medical University of the Russian Federation Ministry of Health; Department of Psychoneurology #2, Russian Children Clinical Hospital of the Russian Federation Ministry of Health.
Zavadenko NN; Neurology, Neurosurgery and Medical Genetics Department of Pediatric Faculty, Pirogov Russian National Research Medical University of the Russian Federation Ministry of Health.
Il Ina ES; Neurology, Neurosurgery and Medical Genetics Department of Pediatric Faculty, Pirogov Russian National Research Medical University of the Russian Federation Ministry of Health; Department of Psychoneurology #2, Russian Children Clinical Hospital of the Russian Federation Ministry of Health.
Kolpakchi LM; Department of Psychoneurology #2, Russian Children Clinical Hospital of the Russian Federation Ministry of Health.
Fedonyuk ID; Neurology, Neurosurgery and Medical Genetics Department of Pediatric Faculty, Pirogov Russian National Research Medical University of the Russian Federation Ministry of Health; Department of Psychoneurology #2, Russian Children Clinical Hospital of the Russian Federation Ministry of Health.
Bembeeva RC; Neurology, Neurosurgery and Medical Genetics Department of Pediatric Faculty, Pirogov Russian National Research Medical University of the Russian Federation Ministry of Health; Department of Psychoneurology #2, Russian Children Clinical Hospital of the Russian Federation Ministry of Health.
Esipova ES; Neurology, Neurosurgery and Medical Genetics Department of Pediatric Faculty, Pirogov Russian National Research Medical University of the Russian Federation Ministry of Health.
-
Transliterated Title:
-
Peptidergicheskaia nootropnaia terapiia pri detskom tserebral'nom paraliche v sochetanii s épilepsieĭ.
-
Źródło:
-
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2017; Vol. 117 (9), pp. 37-42.
-
Typ publikacji:
-
Journal Article
-
Język:
-
Russian
-
Imprint Name(s):
-
Publication: <1995->: Moskva : Media Sfera
Original Publication: Moskva : "Meditsina",
-
MeSH Terms:
-
Anticonvulsants/*therapeutic use
Cerebral Palsy/*complications
Cerebral Palsy/*drug therapy
Epilepsy/*complications
Nootropic Agents/*therapeutic use
Peptides/*therapeutic use
Body Weight ; Child ; Child, Preschool ; Drug Therapy, Combination ; Epilepsy/drug therapy ; Female ; Hospitalization ; Humans ; Infant ; Injections, Intramuscular ; Intercellular Signaling Peptides and Proteins ; Male ; Peptides/adverse effects ; Spasms, Infantile/complications ; Spasms, Infantile/drug therapy
-
Contributed Indexing:
-
Keywords: cerebral palsy; cortexin; epilepsy; polypeptide nootropic drugs
Local Abstract: [Publisher, Russian] Цель исследования. Анализ эффективности и безопасности применения кортексина у пациентов с детским церебральным параличом (ДЦП) и эпилепсией. Материал и методы. Курс кортексина в сочетании с терапией противоэпилептическими препаратами (ПЭП) получали 84 пациента (55 мальчиков и 29 девочек) в возрасте 1-11 лет с ДЦП и эпилепсией. Дозы препарата подбирали в зависимости от возраста и массы тела пациентов, вводили по 5-10 мг внутримышечно в условиях стационара. Результаты и заключение. Добавление кортексина к ПЭП более чем в 2 раза сократило число приступов в сочетании с улучшением моторных функций у 31 (36,9%) пациента. Улучшение моторных функций без существенного урежения эпилептических приступов достигнуто у 15 (17,8%) пациентов. Сокращение частоты эпилептических приступов более чем в 2 раза без существенного эффекта на моторные функции отмечено у 14 (16,7%) пациентов. Не ответили на терапию 23 пациента (27,4%). Аггравация эпилептических приступов на фоне курса кортексина отмечена у пациентки с синдромом Веста (1,2%), что значительно ниже вероятности аггравации приступов на терапии ПЭП. Полипептидный ноотропный препарат кортексин продемонстрировал эффективность и безопасность в применении в качестве дополнительной терапии у детей с ДЦП в сочетании с эпилепсией.
-
Substance Nomenclature:
-
0 (Anticonvulsants)
0 (Intercellular Signaling Peptides and Proteins)
0 (Nootropic Agents)
0 (Peptides)
83270-84-2 (cortexin)
-
Entry Date(s):
-
Date Created: 20171021 Date Completed: 20180326 Latest Revision: 20191210
-
Update Code:
-
20240104
-
DOI:
-
10.17116/jnevro20171179137-42
-
PMID:
-
29053119
-
Aim: To assess the efficacy and safety of сortexin in the treatment of children with cerebral palsy (CP) combined with epilepsy.
Material and Methods: Eighty-four patients (55 boys and 29 girls), aged from 1 to 11 years, with CP combined with epilepsy received cortexin together with antiepileptic drugs (AEDs). Cortexin was administered in doses of 5-10 mg depending on the patient's age and body weight intramuscularly during hospitalization.
Results and Conclusion: Cortexin as add-on to AEDs reduced for more than two times the number of seizures, along with improvement of motor function, in 31 (36.9%) patients. The improvement of motor function, but without a significant decrease in epileptic seizures, was achieved in 15 (17.8%) of the patients. Reduction of epileptic seizures frequency (>2 times), but without a significant effect on motor function, was observed in 14 cases (16.7%). Twenty-three patients (27.4%) did not respond the therapy. The aggravation of epileptic seizures during cortexin therapy was observed in only 1 girl with West syndrome (1.2%), and this was significantly lower than the probability of seizures aggravation on AED. Polypeptide nootropic medication cortexin demonstrated efficacy and safety as adjunctive therapy in children with CP combined with epilepsy.
